Changes in plasma apolipoprotein AI and AII concentrations in murine reactive amyloidosis

Scandinavian Journal of Immunology

Volumn 50, Issue 5, 1999, Pages 475-478

  Yamada, T ^a   Wada, A ^a   Fukuda, T ^b   Itoh, Y ^a   Itoh, K ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; HIGH DENSITY LIPOPROTEIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMYLOIDOSIS; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; BASE SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MICE; MICE, INBRED ICR; RNA, MESSENGER;

EID: 0032718181     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1999.00621.x     Document Type: Article

References (15)

1. Glenner GG. Amyloid deposits and amyloidosis. The β-fibrilloses. New Engl J Med 1980;302:1283-92, 1333-43.
2. Benson MD. Amyloidosis. In: Striver CR, Beaudet AL, Sly WS, Valle DV, eds. The Metabolic Basis of Inherited Disease (7 Edn). New York: McGraw-Hill, 1995:4159-91.
3. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): Biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid Int J Exp Clin Invest 1994;1:119-37.
4. Yamada T, Liepnieks JJ, Benson MD, Kluve-Beckerman B. Accelerated amyloid deposition in mice treated with the aspartic protease inhibitor, pepstatin. J Immunol 1996;157:901-7.
5. Liepnieks JJ, Kluve-Beckerman B, Benson MD. Characterization of amyloid A protein in human secondary amyloidosis: The predominant deposition of serum amyloid AI. Biochim Biophys Acta 1995;1270:81-6.
6. Baba S, Masago SA, Takahashi T, et al. A novel alleic variant of serum amyloid A, SAAIγ: Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic amyloidosis. Hum Mol Genet 1995;4:1083-7.
7. Yamada T, Ozawa T, Gejyo F, et al. Decreased serum apolipoprotein AII/AI ratio in systemic amyloidosis. Ann Rheum Dis 1998;57:249-51.
8. Ran JS, DeLellis RA, Glenner GG. Amyloid III. A method for rapid induction of amyloidosis in mice. Int Arch Allergy 1968:34:201-4.
9. Sipe JD, Gonnerman WA, Loose LD, Knapschaefer G, Xie WJ, Franzblau C. Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA). J Immunol Methods 1989;125:125-35.
10. Godenir NL, Jeenah MS, Coetzee GA, van der Westhuyzen DR, Strachan AG, de Beer FC. Standardization of the quantitation of serum amyloid A protein (SAA) in human serum. J Immunol Methods 1985;83:217-25.
11. Luo CC, Li WH, Moore MN, Chan L. Structure and evolution of the apolipoprotein multigene family. J Mol Biol 1986;187:325-40.
12. Kunisada T, Higuchi K, Aota S, Takeda T, Yamagishi H. Molecular cloning and nucleotide sequence of cDNA for murine senile amyloid protein: Nucleotide substitutions found in apolipoprotein A-II cDNA of senescence accelerated mouse (SAM). Nucleic Acids Res 1986:14:5729-40.
13. Alonso S, Minty A, Bourlet Y, Buckingham M. Comparison of three actin-coding sequences in the mouse. Evolutionary relationship between the actin genes of warm-blooded vertebrates. J Mol Evol 1986;23:11-22.
14. Shirahama T, Cohen AS. Redistribution of amyloid deposits. Am J Pathol 1980;99:539-50.
15. SAA) by murine macrophages in vitro. A light and electromicroscopic investigation. Amyloid Int J Exp Clin Invest 1997;4:259-73.